All In Biotech

Drug Trial Radar · NCT02951156

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

PHASE 1B/PHASE 3 MULTICENTER STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION REGIMENS THAT INCLUDE AN IMMUNE AGONIST, EPIGENETIC MODULATOR, CD20 ANTAGONIST AND/OR CONVENTIONAL CHEMOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) JAVELIN DLBCL

Last checked: Nov 19, 2026Latest source record: Dec 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

29

Actual

Start

Dec 16, 2016

Primary completion

Dec 2, 2019

Study completion Dec 2, 2019

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
EMD Serono
First posted
Nov 1, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in combination with various agents for the treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL).

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

  • AvelumabBiological

    Investigational fully human anti-PD-L1 monoclonal antibody

  • UtomilumabBiological

    Investigational, fully human IgG2 CD 137/4-1BB agonist

  • RituximabBiological

    CD20-directed cytolytic antibody

  • AzacitidineOther

    Antimetabolite antineoplastic agent and demethylation agent.

  • BendamustineDrug

    Alkylating drug

  • GemcitabineDrug

    Nucleoside analogue

  • OxaliplatinDrug

    Platinum-based drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose Limiting Toxicities (DLT)Time frame: Day 1 Cycle 1 up to 4 Weeks
  2. Objective Response Rate (ORR) as Assessed by Investigator Per Lugano Response Classification CriteriaTime frame: Randomization until date of PD, start of new anticancer therapy, discontinuation from study or death due to any cause, whichever occurred first (maximum up to 36 months)

Locations

29 sites in 8 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • Norton Cancer Institute

    Louisville, Kentucky

  • Norton Diagnostic Center - Dupont

    Louisville, Kentucky

  • Norton Women's and Children's Hospital

    Louisville, Kentucky

  • Tulane Medical Center

    New Orleans, Louisiana

  • Parexel International

    Billerica, Massachusetts

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • North Shore Hematology Oncology Associates

    East Setauket, New York

  • St. George Hospital

    Kogarah, New South Wales, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • Cancer Clinical Trials Centre, Austin Health, Level 4

    Heidelberg, Victoria, Australia

  • Genesis Care

    Heidelberg, Victoria, Australia

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Farmacia Studi Clinici

    Rozzano, MI, Italy

  • Istituto Clinico Humanitas

    Rozzano, MI, Italy

  • Nzoz McD Voxel Osrodek Pet-Tk-Nmr

    Krakow, Poland

  • Centrum Onkologii Ziemi Lubelskiej im. Sw. Jana z Dukli Oddzial Hematologiczny

    Lublin, Poland

  • NU-MED Centrum Diagnostyki i Terapii Onkologicznej Zamosc Sp. z o.o.

    Zamość, Poland

  • Malopolskie Centrum Medyczne S.C.

    Krakow, Lesser Poland Voivodeship, Poland

  • Centrum Onkologii Ziemi Lubelskiej im. Sw. Jana z Dukli

    Lublin, Lublin Voivodeship, Poland

  • Samsung Medical Center Clinical Trial Pharmacy

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Hospital San Pedro de Alcantara

    Cáceres, Spain

  • Centro de Investigación Medicina Especializada Sanitaria (CIMES)

    Málaga, Spain

  • Hospital Universitario Virgen de la Victoria

    Málaga, Spain

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

  • The Christie Pathology Partnership

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.